Werewolf Therapeutics, Inc.

HOWL · United States

Share price · HOWL

$1.03+0.62 (+151.71%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (4.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HOWL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 21 Aug 2026+102.6%
  2. 31 Jul 2026-29.4%
  3. 24 Jul 2026+18.5%
  4. 13 Jul 2026-15.3%
  5. 30 Jun 2026+16.9%
  6. 25 Jun 2026-10.8%

    Nothing announced by HOWL that day or the session before.

  7. 19 May 2026-13.5%
  8. 1 Apr 2026+15.1%
  9. 26 Mar 2026+10.6%

    Nothing announced by HOWL that day or the session before.

  10. 11 Mar 2026+13.2%

    Nothing announced by HOWL that day or the session before.

Share of unusual movement by asset

For each asset, the share of HOWL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lecomkafusp alfa
events and moves
3shown from 8 days
WTX-330
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—46%
Sessions with no dated event—54%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
IL-12 receptor (tumor-activated prodrug)Biologic (subtype unspecified)
Non-Hodgkin Lymphoma
Advanced Solid Tumors and Non-Hodgkin Lymphoma
Phase 1
IL-2 receptorProtein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$2.2M$42M$9.9M-$9.0M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$6.2M$22M—$6.6M operating cash flowreport ↗
2026-Q1—$8.2M$47M$14M-$11M operating cash flowreport ↗
2025-Q3—$12M$67M$16M-$15M operating cash flowreport ↗
2025-Q2—$13M$78M$18M-$15M operating cash flowreport ↗
2025-Q1—$13M$93M$18M-$19M operating cash flowreport ↗
2024-Q3—$13M$124M$17M-$12M operating cash flowreport ↗
2024-Q2—$15M$137M$17M-$14M operating cash flowreport ↗
2024-Q1—$13M$160M$16M-$15M operating cash flowreport ↗
2023-Q3—$11M$151M$8.3M-$7.2M operating cash flowreport ↗
2023-Q2—$9.6M$159M$5.1M-$11M operating cash flowreport ↗
2023-Q1—$12M$169M$12M-$9.9M operating cash flowreport ↗
2022-Q3—$13M$142M$12M-$14M operating cash flowreport ↗
2022-Q2—$14M$147M$15M-$0.3M operating cash flowreport ↗
2022-Q1—$11M$145M$15M-$14M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$45M$58M$15M-$60M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$56M$112M$18M-$56M operating cash flowreport ↗
2023-FY—$42M$156M$9.3M-$33M operating cash flowreport ↗
2022-FY—$54M$131M$13M-$41M operating cash flowreport ↗
2021-FY—$35M$159M$13M-$43M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 106 sales ($4.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-07EVNIN LUKE · directorOpen-market sale107,429$0.31$33KForm 4
2026-07-06EVNIN LUKE · directorOpen-market sale35,770$0.32$11KForm 4
2026-06-29EVNIN LUKE · directorOpen-market sale157,084$0.30$47KForm 4
2026-06-17RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale389,216$0.35$136KForm 4
2026-06-17RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale27,695$0.35$10KForm 4
2026-06-16RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale139,686$0.37$52KForm 4
2026-06-16RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale9,939$0.37$4KForm 4
2026-06-15RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale120,216$0.39$47KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 48 reporting institutions held 14.0M shares ($11.6M, 28.8% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.6,681,307$5.6M
2VANGUARD CAPITAL MANAGEMENT LLC1,217,976$1.0M
3MPM BIOIMPACT LLC1,208,810$1.0M
4Lynx1 Capital Management LP657,786$548K
5SPHERA FUNDS MANAGEMENT LTD.626,810$522K
6DC Funds, LP589,102$490K
7Squadron Capital Management LLC563,535$469K
8RENAISSANCE TECHNOLOGIES LLC516,218$430K
9GEODE CAPITAL MANAGEMENT, LLC389,487$324K
10BANK OF AMERICA CORP /DE/264,583$220K
11VANGUARD FIDUCIARY TRUST CO157,726$131K
12MILLENNIUM MANAGEMENT LLC132,050$110K
13STATE STREET CORP119,168$99K
14BlackRock, Inc.101,608$85K
15NORTHERN TRUST CORP86,851$72K